‘Fail First’ Requirement In ACNU Proposal Prompts Adverse Reactions Across US Drug Industry

PhRMA captures tone of its comments saying “proposed rule might play an important role” in making more drugs available OTC. AAM also references gauntlet, saying proposed pathway “would, in theory, broaden the types of nonprescription drugs available to consumers.” CHPA discusses same concerns as well as additional questions for FDA.

• Source: Shutterstock

A broad swath of the US drug industry takes the Food and Drug Administration to task for proposing that sponsors of “additional conditions for nonprescription use” applications first demonstrate conventional labeling wouldn’t support an OTC switch before submitting an ACNU proposal.

The Pharmaceutical Research and Manufacturers of America captures the overall sense of its comments by saying “the proposed rule might...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Rx-to-OTC Switch

More from Health